VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
|Articles|May 18, 2020
Ori Biotech and CellGenix Collaborate on Closed-System, Cell and Gene Therapy Manufacturing
Author(s)BioPharm International Editors
Ori Biotech is partnering with manufacturers and materials suppliers to develop an automated system for cell and gene therapy manufacturing.
Advertisement
Ori Biotech, a London- and Philadelphia-based manufacturing technology company that supplies an automated, closed system for cell and gene therapy (CGT) manufacturing, and CellGenix, a supplier of raw and ancillary materials for CGT and regenerative medicine headquartered in Germany, announced in a May 13, 2020 press release a non-exclusive strategic partnership to achieve closed-system preparation, formulation, and addition of CellGenix media and growth factors within CGT manufacturing for users of the Ori platform.
“Ori Biotech is continuing to build partnerships with best-in-class experts across the cell and gene therapy ecosystem to help enable our vision of integrated, closed-system manufacturing,” said Farlan Veraitch, co-founder and CSO, Ori Biotech, in the press release. “Innovation around the integration of high-quality materials from CellGenix into the Ori full-stack platform is another step toward enabling our customers to have a fully-closed manufacturing process from end-to-end, removing bottlenecks in formulation, preparation, and process flow.”
Ori recently announced a partnership with Achilles Therapeutics to test the application of Ori’s platform with Achilles’ manufacturing process.
“Achilles is excited to start testing the Ori manufacturing platform in our proprietary clonal neoantigen T-cell (cNeT) therapy manufacturing process,” said Ed Samuel, senior vice-president of manufacturing, Achilles Therapeutics, in the April 14, 2020 press release. “Achilles is at a transformational stage in its development with the recent initiation of our first-in-human clinical studies. By harnessing the immune system to destroy cancer cells our cNeT therapy platform could fundamentally change how cancer is treated. Looking to emerging technologies to support our long-term strategy for a fully automated manufacturing process is central to Achilles’ plans for scaling up our production capabilities to deliver personalized cell therapies.”
Source:
Advertisement
Related to this article
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
ProBio grants AbTis exclusive global rights to a discovery-stage oncology antibody for development as a site-specific antibody-drug conjugate.
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
Beam’s base-edited cell therapy met its primary endpoint in the BEACON trial, and a U.S. biologics license application is planned as early as year-end.
AstraZeneca acquired preclinical biotech Omniose, adding a bioconjugation platform for conjugate vaccines against serious bacterial infections.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5